news

$9 million grant awarded to uncover whether Parkinson’s starts in the nose

A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson’s and could aid in the development of novel therapeutics.

Elderly woman using nose spary

The Aligning Science Across Parkinson’s (ASAP) initiative has awarded a $9 million grant to an international team led by the University of Ottawa, Canada, to investigate whether scent-processing nerves that connect the inside of the nose to the brain may play a role in the development of Parkinson’s disease.

“While current treatments can help control some symptoms of Parkinson’s, we cannot stop this disease or even slow it down,” explained team leader Professor Michael Schlossmacher. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention.”

The team includes researchers from Germany and the US and will investigate possible links between environmental exposures in the nasal cavity, inflammation, odour processing centres in the brain and Parkinson’s-related genes, in both animal models and people.   

“We will test the idea that certain environmental triggers, such as viruses, may be able to start a chain reaction in the odour-sensing cells in the nose, resulting in the formation of clumps of a protein called alpha-synuclein,” Schlossmacher elaborated. “If so, we theorise that this process could gradually spread via connections throughout the brain, thereby promoting Parkinson’s, especially in people with multiple risk factors for the disease.”

NEWS: Promising pre-clinical data announced for Parkinson’s drug – READ HERE

More than 80 percent of people with Parkinson’s disease suffer from a reduced sense of smell which often occurs years before the onset of typical movement-related symptoms. “If Parkinson’s does start in the nasal cavity, we might be able to detect early signs of the disease in nasal secretions,” added Dr Brit Mollenhauer, neurologist and associate professor at University Medical Center Goettingen, Germany. “Such a fluid-based biomarker would be invaluable for diagnosis and monitoring of Parkinson’s disease, as well as for clinical trials of new therapies.”

Send this to a friend